Genmab has seen a significant rally with approximately 32.7% increase in 2025, attributed to strong fundamentals and significant pipeline progress. They updated their Articles of Association for increased financial flexibility. This has seen the company's stocks soar 65%, particularly after the under-valued alert by InvestingPro. Genmab's shares have experienced transactions with linked securities and the company has made strides including the acquisition of Merus shares for $8bn. The company's stock has been the spotlight with upgraded ratings by H.C. Wainwright and Truist Securities. Moreover, Genmab's robust demand for Darzalex is significantly driving its growth and the Q3 2025 performance showed a 21% revenue growth, despite a dip in stock. The breakthrough FDA nod and pipeline progress suggests a stronger valuation for the company in the foreseeable future. With recent partnerships and the granting of stock units and warrants to employees, Genmab is being restructured. However, Bernstein reiterated a sell rating on the stock following a 3% drop on J&J’s amivantamab head and neck cancer data.
Genmab Stocks News Analytics from Wed, 02 Apr 2025 07:00:00 GMT to Fri, 28 Nov 2025 04:27:00 GMT -
Rating 8
- Innovation 5
- Information 9
- Rumor 6
